All News

RheumNow Podcast square

Indications Awaiting (12.17.21)

d Jack Cush, MD

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory approvals, plus 3 new cases from rheumatologists.

Read Article
Vaccine2.jpg (keep)

CDC Panel Recommends mRNA COVID Vaccines Over J&J Vaccine

d Jack Cush, MD

The U.S.

Read Article
Cancer,cells

Certain Cancers Increased with Autoimmune Diseases

d Jack Cush, MD

Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer, especially in organ-specific immune-mediated diseases. 

Read Article
Gout pills injection

SGLT2 Inhibitors in Type 2 Diabetes Lowers Gout Risk

d Jack Cush, MD

A recent study of drugs used in type 2 diabetes (T2DM) shows that SGLT2 inhibitors have a lower risk for gout compared with those receiving DPP4 inhibitors.

Read Article
FDA.approved.jpg

Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis

d MedPage Today

The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced on Tuesday.

Read Article
FDA%20approved.jpg (keep)

Rinvoq FDA Approved for Active Psoriatic Arthritis

d Jack Cush, MD

The FDA has approved upadacitinib (Rinvoq) today for use in the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Read Article
CV mortality with infection & inflammation studied using CDC database; From 1999 to 2018 CV mortality decreased in general population (40.9 to 30.6%) but increased w/ HCV (7.0 -10.2%) & HIV (1.9 to 6.7%); decreased in plateaud in IBD, PSO, RA, and SLE https://t.co/Oiv92xRs6W

Links:

Dr. John Cush RheumNow ( View Tweet)

RESTORE trial: yet another failure for PRP injections for knee #OA. Study of 288 Knee oA over 50 years - knee pain scores of −2.1 vs −1.8 on an 11-point scale (range, 0-10) and no difference between PRP and PBO at 12 moshttps://bit.ly/3dZ5ebW

Dr. John Cush RheumNow ( View Tweet)

SOBI has received a positive opinion by the EMA's CHMP on Kineret (anakinra) for the treatment of COVID-19 in adult patients with pneumonia requiring supplemental oxygen or at risk for progressing to severe respiratory failure. Final approval pending https://t.co/1bJYae38hw

Links:

Dr. John Cush RheumNow ( View Tweet)

It has been a absolute honor to serve the rheum community. Your generous friendship and the ideas sparked on this account inspired me. It was a difficult decision, but yesterday was my last official day at @ACRheum. Thank you for 20+ years of pure goodness. https://t.co/sjAQcgQcSh
Donna Hoyne donna_hoyne ( View Tweet)
NRMP has released match results for adult Rheumatology programs. From a total of 125 programs, 120 filled & 98% of Rheum slots (266/272) filled. Rheum was one of few to fill >95% slots (also Allergy, cardiology, Endo, GI, Hem/Onc, Pulm/Critical Care https://t.co/7ASNKwB4ZS https://t.co/7fDrqG2WRM

Links:

Dr. John Cush RheumNow ( View Tweet)
NRMP announced match results for Pediatrics & Specialties. Unfortunately 31% of positions are unfilled (40% programs unfilled). We need more Pediatric Rheumatologists!!! https://t.co/s0zPL7QhIG https://t.co/ufuuWb3rJc

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM Clinical Images - Tongue Necrosis in Giant Cell Arteritis. 74-yoF w/ 3-day hx of HA and tongue swelling/pain, & blindness in the right eye. Tongue was ulcerated, R temporal artery thickened. ESR 42 CRP 169 mg/L. Read rest of story... https://t.co/Npc48trzk6 https://t.co/YfikSZmjWk

Links:

Dr. John Cush RheumNow ( View Tweet)
Might Tofacitinib Reduce Malignancy Risk with Patients with RA? https://t.co/lrBwN6meQR https://t.co/cW2FEGbEaH

Links:

Dr. John Cush RheumNow ( View Tweet)
Cochrane analysis of NSAIDs in acute #Gout - 28 trials, 3406 pts showed: - NSAIDs > PBO 50% pain reduction @24hrs, but = to PBO for AEs & W/D - nonselective NSAIDs = COX-2 inhib, but former has more AE & WD - PRED - NSAIDS, but pred has more AE & WD https://t.co/AemfID4RLN https://t.co/Ex1stFG9WG

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay https://t.co/6Um0la1yRi https://t.co/W4xHBxB2AV

Links:

Dr. John Cush RheumNow ( View Tweet)
Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-Related Arthritis (ERA)- Current Challenges and Future Outlook https://t.co/O6GENGGxKm

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 408 men with inflammatory arthritis fathered 897 singleton pregnancies with 794 live births. Pregnancies conceived after the diagnosis of IA had higher rate of miscarriage (12.3 vs 7.5%, p = <0.05), even after adjusting for confounders (OR 2.03) https://t.co/Nq2lP0SXTL

Links:

Dr. John Cush RheumNow ( View Tweet)

BMS announced today that Orencia as 1st FDA approved drug to prevent acute graft versus host disease & may be used in bone marrow or stem cell transplantation from an unrelated donor. (Based on 186 pt RCT w/ Orencia showing better survival (98 vs 75% PBO) https://t.co/9j9fPEwKJU

Links:

Dr. John Cush RheumNow ( View Tweet)

New podcast up! Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology. Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022. https://t.co/TBX2RvCCB6 https://t.co/LYBoViqmpD

Links:

Dr. John Cush RheumNow ( View Tweet)
×